The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 15, 2023

Filed:

Jun. 18, 2020
Applicants:

Promab Biotechnologies, Inc., Richmond, CA (US);

Forevertek Biotechnology Co., Ltd, Changsha, CN;

Inventors:

Lijun Wu, Albany, CA (US);

Vita Golubovskaya, Richmond, CA (US);

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/46 (2006.01); C07K 16/28 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); A61K 39/00 (2006.01); C07K 14/79 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/2878 (2013.01); A61K 2039/505 (2013.01); C07K 14/79 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01);
Abstract

The present invention is directed to a chimeric antigen receptor fusion protein comprising: (i) a single-chain variable fragment (scFv) comprising Vand V, wherein scFv has an activity against a tumor antigen, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain; wherein the CAR further comprises a human transferrin fragment, which is an epitope for an antibody against human transferrin, at N-terminus or C-terminus to scFv, or between Vand V. Preferred tumor antigens are CD19, CD22 and BCMA. The CD19-TF-CAR-T cells, CD22-TF-CAR-T cells, and BAMA-TF CAR-T cells secrete less cytokines, but they have the same efficacy against cancer target cells when comparing with same CAR without TF.


Find Patent Forward Citations

Loading…